%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
124 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-12T10:21:59Z
2024-03-29T04:34:37-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T04:34:37-07:00
application/pdf
Heather
2004-201.dec
uuid:fa893a95-1dd1-11b2-0a00-7f0927bd7200
uuid:fa893a98-1dd1-11b2-0a00-880000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 10 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
141 0 obj
[146 0 R]
endobj
142 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
52.97 77 m
557.97 77 l
S
0 0 0 0 k
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 540.968 56.9344 Tm
(2471)Tj
ET
0 0 0 0 k
53.03 70.8 203 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.032 57.8698 Tm
(Zih, et al: Specialist clinics for FM)Tj
/T1_2 1 Tf
0.1996 Tw 10 0 0 10 53.5 735.3264 Tm
(from some minimal changes in medication category use,)Tj
0.06 Tw 0 -1.2 TD
(there was no clear pattern indicating major changes in pre-)Tj
0.0327 Tw T*
(scribing practices. Success of a treatment may be measured)Tj
0.159 Tw T*
(by continued use of an agent by the patient. For patients)Tj
0.19189 Tw T*
(with FM, we have observed that anti-depressant medica-)Tj
0.0842 Tw T*
(tions were the most commonly continuously used pharma-)Tj
0.2392 Tw T*
(cologic treatments in 41%, followed by tranquillizers in)Tj
0.0499 Tw T*
[(29%, and NSAID in 27%. )55 (Additionally)65 (, almost one-quarter)]TJ
-0.0215 Tw T*
(of patients with FM were using opioid treatments at the time)Tj
0.0368 Tw T*
[(of the last visit. )55 (Although not approved for the treatment of)]TJ
-0.0166 Tw T*
[(FM, anti-epileptic agents, and gabapentin in particular)40 (, were)]TJ
0.0015 Tw T*
(used by 15% of patients. Non-pharmacologic treatments are)Tj
0.0531 Tw T*
(likely as important in the management of patients with FM)Tj
0.2493 Tw T*
[(as pharmacologic treatments. However)40 (, the use of these)]TJ
0.04089 Tw T*
(interventions was reported by only 9% of patients with FM)Tj
0.05769 Tw T*
[(at the completion of the study)65 (. )55 (Adherence to treatment rec-)]TJ
-0.0085 Tw T*
(ommendations for patients in general is known to be poor)Tj
0 Tc 0 Tw 7.5 0 0 7.5 283.4999 546.6265 Tm
(20)Tj
10 0 0 10 290.9999 543.3264 Tm
(.)Tj
-0.00011 Tc 0.09 Tw -23.75 -1.2 Td
(For these reasons we believe that the care of patients with)Tj
-0.03081 Tw T*
[(FM in this clinic setting did not greatly dif)18 (fer from treatment)]TJ
0.2702 Tw T*
(interventions already prescribed by mostly primary care)Tj
0 Tw T*
(physicians. )Tj
0.0804 Tw 1.2 -1.21 Td
(Limitations of this clinical audit of a FM clinic warrant)Tj
0.09959 Tw -1.2 -1.21 Td
[(attention. )55 (Although the study setting was in a tertiary care)]TJ
0.0966 Tw 0 -1.21 TD
[(academic center)40 (, our patient population was representative)]TJ
0.2188 Tw T*
(of patients with FM regarding demographic information,)Tj
0.08771 Tw T*
(disease duration, and medication use)Tj
0 Tc 0 Tw 7.5 0 0 7.5 203.8979 438.1265 Tm
(17)Tj
-0.00011 Tc 0.08771 Tw 10 0 0 10 211.3979 434.8265 Tm
(. It is possible how-)Tj
0.0416 Tw -15.7898 -1.21 Td
(ever that patients referred to this clinic were preselected by)Tj
-0.0079 Tw T*
(the referring physician as being either more complex or per-)Tj
0.07491 Tw T*
(haps not typical, which could account for the high number)Tj
0.00349 Tw T*
(of other diagnoses identified in this group. In contrast to the)Tj
0.2337 Tw T*
(rigorous confines of a clinical trial setting, the outcome)Tj
0.0986 Tw T*
(measure of improvement was by patient report rather than)Tj
-0.0092 Tw T*
(by use of a standard functional measure. It is notable that no)Tj
0.05231 Tw T*
[(significant dif)18 (ferences were noted in the number of comor-)]TJ
0.0658 Tw T*
[(bid diseases and aller)18 (gies between patients with or without)]TJ
-0.0246 Tw T*
[(FM. )18 (The 1)37 (1 FM patients who failed to return for a scheduled)]TJ
-0.01041 Tw T*
(appointment were categorized as not having benefitted from)Tj
-0.0114 Tw T*
(contact with a specialist clinic. Reasons other than poor out-)Tj
0.15379 Tw T*
(come may have been responsible for missing an appoint-)Tj
-0.0105 Tw T*
[(ment. Even taking these 1)37 (1 patients into account, the overall)]TJ
0.1277 Tw T*
(usefulness of referral to a specialist clinic was positive in)Tj
0.02499 Tw T*
(about three-quarters of the whole cohort.)Tj
-0.02161 Tw 1.2 -1.2 Td
(The ambivalence expressed by attending rheumatologists)Tj
0.26939 Tw -1.2 -1.2 Td
(is likely the result of frustration in the management of)Tj
0.07359 Tw 0 -1.2 TD
(patients with FM, for whom there is limited understanding)Tj
0.3703 Tw T*
(of the disease process and mostly empirical treatment)Tj
0.11211 Tw T*
(options. In this audit of patients referred to a subspecialty)Tj
0.14301 Tw T*
(clinic, we observed that the specialist contact is useful in)Tj
0.007 Tw T*
(over two-thirds of the total patient group, but continued fol-)Tj
-0.0293 Tw T*
(lowup by a specialist is of lesser value. In the context of lim-)Tj
0.20039 Tw T*
(ited health care resources, overburdened health care sys-)Tj
0.0677 Tw T*
(tems, and rising cost of medical care, we believe that once)Tj
-0.0361 Tw T*
(the diagnosis of FM is confirmed, patients can be reasonably)Tj
-0.0146 Tw T*
(managed by primary care physicians. Until the pathogenesis)Tj
0.11549 Tw 26.4 63.81 Td
(of symptoms in FM is better understood, current manage-)Tj
0.00121 Tw T*
(ment remains mostly empirical and based on personal expe-)Tj
0.2061 Tw T*
[(rience rather than sound scientific evidence. )18 (W)80 (e propose)]TJ
0.0257 Tw T*
(that the primary care physician, having a better understand-)Tj
0.10831 Tw T*
(ing of the complete medical and psychosocial background)Tj
0.12691 Tw T*
(of a patient, is likely in a more favorable position to best)Tj
0.02499 Tw T*
(manage patients diagnosed with FM.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 324.5 629.6264 Tm
[(1.)-875 (W)80 (olfe F)80 (, Smythe HA, )37 (Y)111 (unus MB, et al. )18 (The )55 (American College of)]TJ
1.675 -1.2125 Td
(Rheumatology 1990 criteria for the classification of fibromyalgia.)Tj
0 -1.2125 TD
(Arthritis Rheum 1990;33:160-72.)Tj
-1.675 -1.2125 Td
[(2.)-875 (Clauw DJ, Crof)18 (ford LJ. Chronic widespread pain and fibromyalgia:)]TJ
1.675 -1.2125 Td
[(what we know)65 (, and what we need to know)65 (. Best Pract Res Clin)]TJ
T*
(Rheumatol 2003;17:685-701. )Tj
-1.675 -1.2125 Td
[(3.)-875 (W)80 (einblatt ME. )18 (The best of times, the worst of times: rheumatology)]TJ
1.675 -1.2125 Td
[(2001. )55 (Arthritis Rheum 2002;46:567-73.)]TJ
-1.675 -1.2125 Td
[(4.)-875 (White KP)111 (, Speechley M, Harth M, Ostbye )18 (T)74 (. )18 (The London)]TJ
1.675 -1.2125 Td
(Fibromyalgia Epidemiology Study: direct health care costs of)Tj
T*
(fibromyalgia syndrome in London, Canada. J Rheumatol)Tj
0 Tc 0 Tw T*
(1999;26:885-9. )Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.2125 Td
[(5.)-875 (Bennett RM. Beyond fibromyalgia: ideas on etiology and treatment.)]TJ
1.675 -1.2125 Td
(J Rheumatol 1989;16:185-91.)Tj
-1.675 -1.2125 Td
[(6.)-875 (Schochat )18 (T)74 (, Raspe H. Elements of fibromyalgia in an open )]TJ
1.675 -1.2125 Td
(population. Rheumatology 2003;42:829-35. )Tj
-1.675 -1.2125 Td
[(7.)-875 (Holman )55 (AJ. )18 (The value of rheumatologists to patients with)]TJ
1.675 -1.2125 Td
[(fibromyalgia: comment on the presidential address by )18 (W)80 (einblatt.)]TJ
T*
(Arthritis Rheum 2002;46:3390.)Tj
-1.675 -1.2125 Td
[(8.)-875 (W)80 (einblatt ME. Reply to: )18 (The value of rheumatologists to patients)]TJ
1.675 -1.2125 Td
[(with fibromyalgia: comment of presidential address by )18 (W)80 (einblatt.)]TJ
T*
(Arthritis Rheum 2002;46:3390.)Tj
-1.675 -1.2125 Td
[(9.)-875 (Fitzcharles MA, Esdaile JM. )18 (The overdiagnosis of fibromyalgia)]TJ
0 Tc 1.675 -1.2125 Td
[(syndrome. )55 (Am J Med 1997;103:44-50. )]TJ
-0.00011 Tc -2.175 -1.2125 Td
[(10.)-875 (Fitzcharles MA, Boulos P)111 (. Inaccuracy in the diagnosis of)]TJ
2.175 -1.2125 Td
(fibromyalgia syndrome: analysis of referrals. Rheumatology)Tj
0 Tc 0 Tw T*
(2003;42:263-7.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.2125 Td
[(1)37 (1.)-875 (Buskila D, Neumann L, Sibirski D, Shvartzman P)111 (. )55 (A)92 (wareness of)]TJ
2.1381 -1.2125 Td
(diagnostic and clinical features of fibromyalgia among family)Tj
T*
(physicians. Family Pract 1997;14:238-41.)Tj
-2.175 -1.2125 Td
[(12.)-875 (Barkhuizen )55 (A. Rational and tar)18 (geted pharmacologic treatment of)]TJ
2.175 -1.2125 Td
[(fibromyalgia. Rheum Dis Clin North )55 (Am 2002;28:261-90.)]TJ
-2.175 -1.2125 Td
[(13.)-875 (Granges G, Zilko P)111 (, Littlejohn GO. Fibromyalgia syndrome: )]TJ
2.175 -1.2125 Td
(assessment of the severity of the condition 2 years after diagnosis. )Tj
T*
(J Rheumatol 1994;21:523-9.)Tj
-2.175 -1.2125 Td
[(14.)-875 (Martinez JE, Ferraz MB, Sato EI, )55 (Atra E. Fibromyalgia versus)]TJ
2.175 -1.2125 Td
(rheumatoid arthritis: a longitudinal comparison of quality of life. )Tj
T*
(J Rheumatol 1995;22:270-4.)Tj
-2.175 -1.2125 Td
[(15.)-875 (MacFarlane GJ, )18 (Thomas E, Papageor)18 (gious )55 (AC, Schollum J, Croft)]TJ
2.175 -1.2125 Td
[(PR, Silman )55 (AJ. )18 (The natural history of chronic pain in the )]TJ
T*
(community: a better prognosis than in the clinic? J Rheumatol)Tj
0 Tc 0 Tw T*
(1996;23:1617-20.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2125 Td
[(16.)-875 (Fitzcharles MA, Da Costa D, Poyhia R. )55 (A)-220 (study of standard care in)]TJ
2.175 -1.2125 Td
(fibromyalgia syndrome: a favorable outcome. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:154-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2125 Td
[(17.)-875 (W)80 (olfe F)80 (, )55 (Anderson J, Harkness D, et al. Health status and disease)]TJ
2.175 -1.2125 Td
[(severity in fibromyalgia: results of a six-center study)65 (. )55 (Arthritis)]TJ
0 Tc T*
(Rheum 1997;40:1571-9.)Tj
-0.00011 Tc -2.175 -1.2125 Td
[(18.)-875 (Goldenber)18 (g DL. Fibromyalgia syndrome. )55 (An emer)18 (ging but )]TJ
2.175 -1.2125 Td
[(controversial condition. JAMA)-220 (1997;257:2782-7.)]TJ
-2.175 -1.2125 Td
[(19.)-875 (White KP)111 (, Speechely M, Harth M, Ostbye )18 (T)74 (. Fibromyalgia in)]TJ
2.175 -1.2125 Td
(rheumatology practice: a survey of Canadian rheumatologists. )Tj
T*
(J Rheumatol 1995;22:722-6.)Tj
-2.175 -1.2125 Td
[(20.)-875 (Agras )18 (WS. Understanding compliance with the medical regimen:)]TJ
2.175 -1.2125 Td
[(the scope of the problem and a theoretical perspective. )55 (Arthritis)]TJ
T*
(Care Res 1989;2:S2-S7.)Tj
ET
0 0 0 0 k
/GS0 gs
101.13 80.08 407.5 -10.83 re
f*
0.5 w
101.13 80.08 407.5 -10.83 re
S
Q
Q
q
1 0 0 1 0 -1 cm
0 0 612 792 re
W n
1 0 0 1 0 1 cm
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_4 8 Tf
112.368 72 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\7>AaNt#itt$j>r:3k%/$AYa\7%:m@"M$Sqkh#Ou;Ra8fP=WI6k0lj%NIdO&qP
@p)n2*KH:@a`6a@MtI:7%;bJe\1_;Kb,AS&aNNSsS=ro`R1p[^Mo]*O9Fca4F(NIp
b@h"e)`FLqp96e[la_.CiA,P$^c]IC^`n(^PlX-u4]M"mK:UBlnSlI2Nl67W";McU
b&nDq)-e1P_.3oF5.Vso?m!.U-/V!/:]fV^^f.P?8[Qc*pb&'E+Yqgfq0
TN!_&,8s[_pB8B(Dr=Da=O8RSI+W1?pBPZbN:.gBoWk[BceM@!^1VOH(=HMI(uJ,H
1O:EI$92eb:n]B2="C)8MF9TJMmcc.WmtpD$`Im7VSg5qeC4&C.S'ksLR,]5oUq[f
Y9P4ukHnQ>9uGgJY&TRpjsoOiM5a[#E00s]RXlM[.s[7eG8FfJa]NbH5u?/t:P0W-
2\i%p\dN,%hBNF[Zj]X!Bca[`HZPI^Zl\mC]YsB#5l4?CS"+Uo&Ch
a+Dn5MQ#G*_/tLGM=fo*&*NHI3PrV#3OU1eDH[$&Rcf\g<`4cEU
XYKp`~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
87 0 obj
<>
endobj
41 0 obj
<>
endobj
43 0 obj
<>
endobj
63 0 obj
<>
endobj
78 0 obj
<>
endobj
130 0 obj
<>
endobj
62 0 obj
<>
endobj
73 0 obj
<>stream
HLPgw /\ure,6r-JQQsJII I XTUX="PK^-ӛڞֱwgiϮof]<μ}DdAdLf֪+l][z( i)͍843R2D˰aåw|T[;Ut<3FГ1EQgEƤg`}0_Z"V3Uf.uYBt2sBO\5BrX)ou&L0KMB Vi_MoUʷEV`5~|iTy!H"^C,3"L9#nMMS#G
@eP]b֊vZ'/șnSO'^4iּ]""kpS} 撞t'fWk8@a?Y=`z)%y>[V\o[vpdy=@O[raz¹wF0A,~PՐ`AtO<0c{j|Mڀ}jd7<27`.nu$[]HhjְA!Dkqb9R k3JɡR䩩*o]g6<'6RSPWlW5/hu@=p츶noh==`W zzȀsb%yWFObʩxpL#u
MVjG&kK